The Study of rs693 and rs515135 in APOB in People with Familial Hypercholesterolemia

Fatemeh Karami, M.Sc.¹, Iman Salahshourifar, Ph.D.¹, Massoud Houshmand, Ph.D.²*

1. Department of Biology, Science Faculty, Science and Research Branch, Islamic Azad University, Tehran, Iran
2. Department of Medical Genetics, National Institute for Genetic Engineering and Biotechnology, Tehran, Iran

*Corresponding Address: P.O.Box: 14965/161, Department of Medical Genetics, National Institute for Genetic Engineering and Biotechnology, Tehran, Iran

Email: massoudh@nigeb.ac.ir

Received: 4/Jan/2018, Accepted: 3/Jun/2018

Abstract

Objective: APOB-related familial hypercholesterolemia (FH) is the most common hereditary hypercholesterolemia with an autosomal dominant pattern. A number of APOB variants are the most important risk factors for hypercholesterolemia. APOB is a large glycoprotein that plays an important role in the metabolism of lipoproteins in the human body. Small changes in the structure and function of APOB can cause major problems in lipid metabolism. Two forms of APOB are produced by an editing process of gene replication. APOB48 is required for the production of chylomicrons in the small intestine and APOB100 is essential in liver for the production of very low density lipoprotein (VLDL) and is also a ligand for LDL receptor (LDLR) that mediates LDL endocytosis.

Materials and Methods: In this case-control study, rs693 (in exon 26 of APOB) and rs515135 (5 ’end of APOB) single nucleotide polymorphisms (SNPs) were analyzed in 120 cases of familial hypercholesterolemia and 120 controls. Both SNPs were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) where PCR products were digested with specific restriction enzymes recognizing each single nucleotide polymorphism.

Results: This study was analyzed by odds-ratio (OR) and its 95% confidence interval (CI) to examine the association of the two SNPs with familial hypercholesterolemia susceptibility. Statistical analysis showed that both SNPs were in Hardy-Weinberg equilibrium.

Conclusion: We found no significant relationship between rs515135 and familiar hypercholesterolemia. However, there was a significant association between the C allele of rs693 and high familial cholesterol levels. Furthermore, it seems the dominant model of T allele occurrence has a protective role in emergence of disease.

Keywords: APOB, Familial Hypercholesterolemia, Single Nucleotide Polymorphism

Cell Journal(Yakhteh), Vol 21, No 1, Apr-Jun (Spring) 2019, Pages: 86-91

Introduction

Familial hypercholesterolemia (FH) is a monogenic inherited disorder. The FH heterozygote type has a two- to three-fold increase in low-density lipoprotein (LDL) cholesterol in serum and has a prevalence of 0.2% (at least 1 in 500) in most countries (1-3). The frequency of homozygous FH is 1 in a million and has a six- to eight-fold increase in plasma LDL-cholesterol (LDL-c) with signs appearing in childhood (1, 4). To reduce the risk of atherosclerosis and premature cardiovascular complications, clinical management focuses on early diagnosis of FH (5). The available evidence demonstrates that FH results from a combination of genetic variants and environmental (diet risk factors and tobacco smoking) factors in different populations (3, 6, 7). Genetic predisposition is assumed to be the cumulative result of mutations and/or polymorphisms of genes that may even have a small-effect, leading to a slight increase in LDL-C (8). Detection of heterozygote and homozygote FH in affected family members is an important step for success rate in accurate diagnosis and subsequent family screening (2).

Given that FH is one of the sole risk factors of coronary heart disease (CHD), identifying FH causing variants and classifying patients into possible FH is important (9). The majority of cases with FH could be explained by genetic mutations in LDLR, APOB, PCSK9 and LDLRAP1 (10). APOB is the well-known gene that encodes the protein involved in LDL. The defect in apo B-100 receptor binding domain (Arg3500→Gln) is the most prevalent cause of ligand-defective LDL and cause of FH. Mutations or polymorphisms in APOB have been described as causal risk factors of FH (2, 3, 8, 11).

The APOB gene is approximately 43kb in size, and consists of 29 exon and is located on the short arm of chromosome 2 (2 p24.1) (12). Susceptible single nucleotide polymorphisms (SNPs), the most common type of genetic variation, are known to be markers of different chromosomal loci in heritable disease (13). Genome-wide association study (GWAS) focuses on cognizance of SNPs as biomarkers of a disease which have been used in numerous biomedical studies (14, 15). As mentioned above, genotyping SNPs helps in the early detection of some patients with genetic susceptibility (6, 13).

The results of the SNP studies must be expounded circumspectly, as these results may be applied exclusively or multiple SNPs can work cooperatively and create a
functional difference. Interplay among multiple SNPs may commonly affect the risk of a disease. Evaluation of SNPs may be problematic with respect to SNP-SNP interactions, because taking the individual SNPs without considering SNP-SNP interactions hinders the discovery of weak achievements (16-19). The frequency of the clinical phenotype of FH has been estimated at almost 0.002 in the general population, but in some isolated populations, like French Canadians, Finns, Afrikaners, Druze and Lebanese, occurrence of FH can be in a higher-than-normal frequency because of founder effects and de novo mutations in a population (20, 21). Data on allele and genotype frequencies for APOB have been reported for European (22, 23) and Asian (24-26) populations. For example, allele frequencies of APOB and the relationship of its genotypes with plasma lipid and lipoprotein levels in the Mongolian Buryat population resembled the Indians but their frequency distribution differed significantly from the Chinese, Malaysians, and Caucasians (25).

At present, the molecular basis of FH has been shown in detail in many populations, but there is still very limited molecular data relating to FH in Iran (20). To investigate associations between the ApoB genotype and levels of LDL-C, two SNPs of APOB, referred to in more than one study (3, 18, 19), were examined to determine the role of these SNPs in developing FH in Iran. There has been no independent study on the genetic association of rs693 and rs515135 with FH in Iran. There has been no independent study on the genetic association of rs693 and rs515135 frequencies in FH cases in Iran. A P<0.01 was considered as statistically significant on chi-square and 95% confidence interval (CI) tests based on Graphpad (https://www.graphpad.com/) and Medcalc to perform the statistical analysis.

Materials and Methods

One hundred and twenty patients with FH, recruited from Karaj hospital, and 120 healthy persons, as the control group, were included in this study. The clinical characteristics of patients including age, gender, familial heart and brain disease, and familial high cholesterol were collected. Mean age of patients was 48.65 ± 14.02 years. All the participants were informed about the study and signed a written consent form. This study was approved by the Ethical Committee in Karaj Hospital.

Blood sample and DNA isolation

Blood samples were collected in tubes containing EDTA (Golden Vac., China). Genomic DNA was extracted with a DNA extraction kit (MBST, Iran) according to the manufacturer’s instructions. The extracted DNA samples were stored in a freezer at -20°C until further use.

Genotyping of APOB rs693, rs515135 polymorphism

The case and control samples were genotyped for rs515135 and rs693 SNP using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).

Oligonucleotide primers for rs693 C>T were:
F: 5’ AGA GGA AAC CAA GCC CAC AGT TGC3’
R: 5’ TAC ATT CGG TCT CGT GTA TCT TCT3’

and the oligonucleotide primers for rs515135 A>G were:
F: 5’ CCT AGT TAA TCA GAA TGA CAC TG3’
R: 5’ ATT GGG GTG GCA ATA GGC GCA AAT TG3’.

PCR amplification was carried out in a total volume of 25 μl consisting of 12.5 μl Master Mix (Tris-HCl, pH=8.5, 1.5 mM MgCl₂, 0.2% Tween-20, 0.4 mM dNTP, 2 U/μl Amplicon Taq DNA polymerase, stabilizer and inert red (Amplicon Co., Denmark), 0.5 μM of each primer and 100 ng DNA template and ddH₂O. PCR cycles were an initial denaturation step at 95°C for 4 minutes followed by 35 cycles of denaturation at 95°C for 30 seconds, annealing temperature of 58°C for 30 seconds, extension at 72°C for 1 minute, and a final extension step at 72°C for 10 minutes.

PCR products were digested with 0.5 μL (10 U) of BglIII (Fermentase, Canada) for rs515135 A>G and XbaI (Fermentase, Canada) for rs693C>T at 37°C for 16 hours. The digested fragments were separated on a 2% agarose gel plate and observed under UV light.

The BglIII recognition site is represented by the presence of G allele which produces two fragments of 108bp and 261 bp, while the presence of A allele is represented by the remaining uncut fragment of 369 bp. The XbaI recognition site is represented by the presence of T allele which produces two fragments of 26 bp and 110 bp, while the presence of C allele is represented by the remaining uncut fragment of 136 bp. The fragments were separated by 2% agarose gel electrophoresis and then visualized under UV light.

Sequencing analysis

The PCR products were examined for specificity using 2% agarose gel electrophoresis. Double-stranded DNA automated sequencing was performed by using an ABI capillary sequencing machine (Applied Biosystems, gene Fanavaran Company, Iran). All fragments were sequenced with the forward primers. Sequence variants were analyzed using FinchTV (http://www.geospiza.com/finchtv/) (Fig.1).

Statistical analysis

Statistical analysis was conducted using Graphpad (https://www.graphpad.com/) and Medcalc to perform the chi-square and 95% confidence interval (CI) tests based on APOB rs693 and rs515135 frequencies in FH cases in Iran. A P<0.01 was considered as statistically significant.

Results

The clinical characteristics of the case and control groups were first compared (Table 1).
Study of Two Polymorphism in APOB Gene

Table 1: Demographic characteristics of the FH case group and the healthy control group

| Variable                        | Case           | Control        | Total | P value |
|---------------------------------|----------------|----------------|-------|---------|
|                                 | n=120          | n=120          | n=240 |         |
| Age (Y, mean ± SD)              | 48.65 ± 14.02  | 41.35 ± 11.15  | -     |         |
| Age of disease onset (Y, mean ± SD) | 40.46 ± 9.61  | NA             | -     |         |
| Age (Y), n (%)                  |                |                |       |         |
| <45                             | 53 (44.16)     | 79 (65.83)     | 132 (55) | 0.0001 |
| 45-60                           | 41 (34.17)     | 35 (29.17)     | 76 (31.67) |       |
| >60                             | 26 (21.67)     | 6 (5)          | 32 (13.33) |       |
| Gender                          |                |                |       |         |
| Female                          | 60 (50)        | 35 (29.17)     | 95 (39.58) | 0.0015 |
| Male                            | 60 (50)        | 85 (70.83)     | 145 (60.42) |       |
| Cholesterol (mg/dl)             |                |                |       |         |
| <200                            | 27 (22.5)      | 120 (100)      | 147 (61.25) |       |
| 200-220                         | 66 (55)        | 0 (0)          | 66 (27.5) | >0.0001 |
| >220                            | 27 (22.5)      | 0 (0)          | 27 (11.25) |       |
| Familiar heart and brain disease|                |                |       |         |
| Yes                             | 56 (46.67)     | 18 (15)        | 74 (30.83) | >0.0001 |
| No                              | 64 (53.33)     | 102 (85)       | 166 (69.17) |       |
| Familiar high cholesterol       |                |                |       |         |
| Yes                             | 12 (100)       | -              | -     |         |
| No                              | NA             | -              | -     |         |

NA; Not available and FH; Familial hypercholesterolemia.
To confirm the results of RFLP, 10 samples were sent for sequencing from both SNPs. According to Table 2, in 120 patients group, 84 patients had CC genotype and 36 patients had TT or CT genotypes. In 120 control groups, 103 patients with CC genotype and 17 with TT and CT genotypes were observed. There was a significant correlation between the CC genotype in the patient group and high familial cholesterol (P=0.0037). Table 3 shows the frequency of GG, AA and GA genotypes in patients with high familial cholesterol and the control group.

**Statistical analysis of rs515135 and rs693 in APOB in the Iranian population**

Results of logistic regression analysis showed no significant correlation between genotype and familial high cholesterol disease (Table 4). Regarding the results of logistic regression modeling, there was no significant relationship between genotype and high familial cholesterol patients (P=0.67). Regarding allelic frequencies of rs693 in both groups, the C allele is the prevalent allele in both groups. There was a significant correlation between the C allele and familial high cholesterol.

| Genotype | Case n (%) | Control n (%) | Total | P value | OR | 95% CI | df |
|----------|------------|---------------|-------|---------|----|--------|----|
| rs515135 |            |               |       |         |    |        |    |
| AA       | 3 (2.5)    | 2 (1.67)      | 5     | -       | Ref (1) | - | 2 |
| GG       | 82 (68.33) | 85 (70.83)    | 167   | 0.6336  | 1.5549 | 0.2533-9.5464 |
| GA       | 35 (29.17) | 33 (27.5)     | 73    | 0.7136  | 1.4141 | 0.2221-9.0068 |
| Total    | 120        | 120           | 240   | -       | -    | -      | 2 |
| rs693    |            |               |       |         |    |        |    |
| TT       | 4 (3.33)   | 1 (0.83)      | 5     | -       | Ref (1) | - |
| CC       | 84 (70)    | 103 (85.84)   | 100   | 0.1585  | 4.9048 | 0.5377-44.74 |
| CT       | 32 (26.67) | 16 (13.33)    | 125   | 0.5499  | 2.0000 | 0.2062-19.3983 |
| Total    | 120        | 120           | 240   | -       | -    | -      |

OR; Odd ratio, CI; Confidence interval, and df; Degrees of freedom.

| Genotype | Patients n (%) | Controls n (%) | Total | P value | 95% CI | df |
|----------|----------------|----------------|-------|---------|--------|----|
| GG+GA    | 117 (97.5)     | 118 (98.33)    | 135   | 0.6535  | 0.2482-9.2201 | 1 |
| AA       | 3 (2.5)        | 2 (1.67)       | 5     |         |        |    |
| Total    | 120            | 120            | 240   |         |        |    |

CI; Confidence interval and df; Degrees of freedom.

| Genotype | Patients n (%) | Controls n (%) | Total | P value | 95% CI | df |
|----------|----------------|----------------|-------|---------|--------|----|
| CT+TT    | 36 (30)        | 17 (141.17)    | 53    |         |        | 1  |
| CC       | 84 (70)        | 103 (85.83)    | 187   | 0.0037  | 1.362-4.949 |    |
| Total    | 120            | 120            | 240   |         |        |    |

CI; Confidence interval and df; Degrees of freedom.
Comparison of variables such as age, sex, cholesterol and history of cardiovascular disease in both control and patient groups showed significant differences. With regard to the incidence and history of cardiovascular disease, the results indicate that in patients with high cholesterol, incidence of cardiovascular disease is higher than healthy people, thus indicating a potential genetic link between hypercholesterolemic family and heart disease. The significance of HWE testing in population-based genetic association studies is immense especially when analyzing the control group. This is because an important assumption underlying these studies is that the control group is a representative sample of the population under investigation. Another assumption in such studies is that individuals of both case and control groups belong to the same single large random-mating population.

In this study Hardy-Weinberg equilibrium for the alleles studied in rs515135 and rs693 polymorphisms in the APOB gene and the unbalance of G and T was established (P>0.05).

Discussion

Of the theoretical estimated prevalence of 1/500 for heterozygous FH, <1% are diagnosed in most countries. Recently, direct screening in a Northern European general population diagnosed approximately 1/200 with heterozygous FH. All reported studies document the failure to achieve the recommended LDL cholesterol targets in a large proportion of individuals with FH, which may have up to 13-fold increased risk of CHD. Based on prevalences between 1/500 and 1/200, between 14 and 34 million individuals worldwide have FH (22).

Early detection and treatment probably would reduce premature morbidity and mortality of this disease. Cascade screening of family members of known index cases is the most cost-effective approach for identification of new FH cases (23). Once diagnosed, individuals with FH can be treated with lifestyle measures, lipid-lowering therapies, and possibly novel therapies including PCSK9 monoclonal antibodies, anti-sense oligonucleotides targeting APOB and microsomal triglyceride transfer protein inhibitors to change the clinical course of the disease (22).

This is the first study investigating the association of APOB polymorphisms with FH. This study provides an analysis of two APOB polymorphisms and their correlation with variation in serum lipid levels in the Iranian population. Significant findings were observed for the genetic association between APOB (rs515135) and (rs693) polymorphisms with variation in TC genotype levels among the Iranian samples analyzed. Heterozygous samples at the APOB rs693 locus were significantly associated with lower TC serum levels. This may suggest an interaction between the two alleles to influence serum TC levels and thus genetically predispose individuals to dyslipidemia.

Univariate analysis of the APOB rs693 polymorphism revealed a significant association between carriers of the allele with lower mean serum TC. These abnormalities in lipid profile associated with the APOB rs693 polymorphism may be the result of a change in the degree of hydrophobicity and efficacy of APOB processing (24-26). Moreover, there was no statistically significant difference in plasma levels of the total cholesterol with respect to the APOB rs515135 SNP.

Among our studied population, the rare T allele was observed may be have a “protective” role exhibiting decrease in the risk of high TC levels in individuals homozygous for the rare T allele. Some of the subjects in the present study with positive family history of hypercholesterolemia (n=120) also showed a significant association with the rare T allele where there was a higher frequency of heterozygotes (26.67%). Logistic regression analysis also showed a significantly lower TC levels in individuals with the homozygous TT genotype.

Conclusion

In this study no significant relationship was found between rs515135 and familiar hypercholesterolemia. However, there was a significant association between the C allele of rs693 and high familial cholesterol levels.

Acknowledgements

The authors of this study would like to appreciate all patients with FH disorder from Karaj city, Iran, for blood donation. The authors would like to express their utmost gratitude to Masoume Dehghan and Parvin Pishva from Medical Genetic Department, Metabolic Center of TUMS for providing practical support to conduct this study. The
The authors declare there is no conflict of interest. The authors would like to express their utmost gratitude to NIHEG for providing financial support to conduct this study.

**Authors’ Contributions**

F.K.; Performed the experiments and contributed to reagents, materials, analysis tools, wrote the manuscript, contributed to the discussion, and reviewed the manuscript.  
I.S.; Conceived and designed the experiments. M.H.; Analyzed the data. All the authors read and approved the final manuscript and contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.

**Reference**

1. Ekrami M, Torabi M, Ghaifouri-Fard S, Mowla J, Mohammad Soltani B, Hashemi-Gorji F, et al. Genetic analysis of Iranian patients with familial hypercholesterolemia. Iran Biomed J. 2018; 22(2): 117-122.  
2. Faiz F, Nguyen LT, van Bockxmeer FM, Hooper AJ. Genetic screening to improve the diagnosis of familial hypercholesterolemia. Clin Lipidol. 2014; 9(5): 523-532.  
3. Tragante V, Asselbergs FW, Swerdlow DI, Palmer TM, Moore JH, de Bakker PI, et al. Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk. Hum Genet. 2016; 135(5): 453-467.  
4. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007; 4(4): 214-225.  
5. Lye SH, Chaih JK, Bagali P, Alex L, Vadivelu J, Ahmad WA, et al. Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia. PLoS One. 2013; 8(4): e60729.  
6. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet. 2008; 40(2): 161-169.  
7. Ahmad F, Mortazavi Y, Fouladsaz K, Mazloomzadeh S. Association of the 12669G>A apolipoprotein B gene polymorphism with apo-B serum level and lipid profile in patients with coronary artery disease comparing with individuals without coronary artery disease in Zanjan population of Iran. Indian J Clin Biochem. 2016; 31(3): 315-320.  
8. Paththiningge CS, Sirisena ND, Dissanayake V. Genetic determinants of inherited susceptibility to hypercholesterolemia-a comprehensive literature review. Lipids Health Dis. 2017; 16(1): 103.  
9. Futema M, Plagnol V, Li K, Whitall RA, Neil HA, Seed M, et al. Whole exome sequencing of familial hypercholesterolemia patients negative for LDLR/APOB/PCSK9 mutations. J Med Genet. 2014; 51(8): 537-544.  
10. Paththiningge CS, Sirisena ND, Dissanayake VHW. Genetic determinants of inherited susceptibility to hypercholesterolemia—a comprehensive literature review. Lipids Health Dis. 2017; 16: 103.  
11. Fisher E, Scharmagl H, Hoffmann MM, Kusterer K, Wittmann D, Wieland H, et al. Mutations in the apolipoprotein (apo) B-100 receptor-binding region: detection of apo B-100 (Arg3500→Trp) associated with two new haplotypes and evidence that apo B-100 (Glu3405→Gln) diminishes receptor-mediated uptake of LDL. Clin Chem. 1999; 45(7): 1026-1038.  
12. Ludwig EH, Blackhart BD, Pierotti VR, Caiati L, Fortier C, Knott T, et al. DNA sequence of the human apolipoprotein B gene. DNA. 1987; 6(4): 363-372.  
13. Hubacek JA, Adamkova V, Lanska V, Dlouha D. Polygenic hypercholesterolemia: examples of GWAS results and their replication in the Czech-Slovakian population. Physiol Res. 2017; 66 Suppl 1: S101-S111.  
14. Festen EA, Goyette P, Green T, Boucher G, Beauchamp C, Trynka G, et al. A meta-analysis of genome-wide association scans identifies IL18RAP, PTPN2, TAGAP, and PUS10 as shared risk loci for Cohn’s disease and celiac disease. PLoS Genet. 2011; 7(11): e1002183.  
15. Egan KM, Thompson RC, Nabors LB, Olson JJ, Brat DJ, LaRocca RV, et al. Cancer susceptibility variants and the risk of adult giloma in a US case-control study. J Neurooncol. 2011; 104(2): 535-542.  
16. Liu X, Wang Y, Qu H, Hou M, Cao W, Ma Z, Wang H. Associations of polymorphisms of rs693 and rs1042031 in apolipoprotein B gene with risk of breast cancer in Chinese. Jpn J Clin Oncol. 2013; 43(4): 362-368.  
17. Asadi E, Farashahi Yazd E, Sheikhia MH, Ghasemi N, Zafaranyegan R. Familial Hypercholesterolemia: From Diagnosis to Treatment. Iranian journal of diabetes and obesity. 2014; 4(6): 186-196.  
18. Vasais AD. Familial hypercholesterolaemia. Clin Biochem Rev. 2004; 25(1): 49-68.  
19. Nordstedtgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013; 34(45): 3478-3490a.  
20. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2000; 4(29): 1-123.  
21. Visvikis S, Shan L, Siest G, Drouin P, Boenwickle E. An insertion deletion polymorphism in the signal peptide of the human apolipoprotein B gene. Hum Genet. 1990; 84(4): 373-375.  
22. Xu CF, Tikkannen MJ, Huttunen JK, Pihlola P, Bütter R, Humphries S, et al. Apolipoprotein B signal peptide insertion/deletion polymorphism is associated with Ag epitopes and involved in the determination of serum triglyceride levels. J Lipid Res. 1990; 31(7): 1255-1261.  
23. Talmud P, Lins L, Brasseur R. Prediction of signal peptide functional properties: a study of the orientation and angle of insertion of yeast invertase mutants and human apolipoprotein B signal peptide variants. Protein Eng. 1996; 9(4): 317-321.